Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ingrezza

Property	Description
Active ingredient	Valbenazine (as Valbenazine tosylate)
Form	Capsule
Pharmacological class	Selective Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Common use	Management of movement disorders
Origin	Synthetic small molecule drug

Ingrezza is a prescription-only medication classified as a Selective Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor, designed to regulate specific chemical signaling in the brain. The primary active ingredient is Valbenazine, a synthetic small molecule drug supplied in a capsule form for oral administration. As a VMAT2 inhibitor, Valbenazine plays a role within neurological agents by modulating specific neurotransmitter pathways. Unlike older agents in this category, Ingrezza is characterized by its selectivity for VMAT2.

The core mechanism involves modulating the action of the VMAT2 protein pump. This pump is vital for packaging and storing monoamine neurotransmitters, such as dopamine, within nerve endings. Valbenazine acts as an agent that reduces dopamine release by inhibiting VMAT2, a process intended to stabilize motor function. This medication works by addressing the underlying chemical processes linked to certain unwanted motions.

Ingrezza's Function and General Therapeutic Purpose

The overall therapeutic purpose of Ingrezza is the pharmacological management of involuntary, unwanted movement disorders that stem from neurological imbalances. The drug achieves its goal by leveraging its targeted action to control the excessive or disorganized signaling of dopamine, a critical factor in motor control pathways. VMAT2 inhibitors like Valbenazine are designed to normalize the flow of these neurotransmitters to improve motor stability. The intended benefit is to promote a more stable and regulated system for managing excessive muscle activity, thereby addressing the fundamental neurochemical dysregulation.

Regulatory References

NIH DailyMed, Ingrezza Label

What side effects are possible with Ingrezza?

Possible Side Effects and Safety Information

Ingrezza (Valbenazine) has a regulatory safety profile categorized by the frequency of adverse reactions observed in clinical studies and documented serious risks.

Frequency-Classified Adverse Reactions

The most common adverse reaction, classified as Very Common (occurring in 10% or more of patients and at least twice the rate of placebo), is somnolence (a term including fatigue and sedation).

Common adverse reactions (occurring in ge 2% and greater than placebo) reported in official labeling include:

Anticholinergic effects (a composite including dry mouth and constipation)
Balance disorders or falls
Headache
Akathisia (restlessness)
Vomiting and Nausea
Arthralgia (joint pain)

Serious Adverse Reactions and Safety Restrictions

The official labeling includes documentation of severe, clinically significant risks:

Depression and Suicidal Ideation/Behavior: A Boxed Warning is included for patients with Huntington's disease, noting an increased risk for these events. Close observation is required when treatment is initiated or the dosage is changed.
QT Prolongation: The medication may prolong the QT interval, a heart rhythm issue. It is contraindicated in individuals with congenital long QT syndrome or a history of associated arrhythmias.
Neuroleptic Malignant Syndrome (NMS) and Parkinsonism: These rare but serious conditions have been reported with dopamine-reducing agents, including Valbenazine.
Hypersensitivity Reactions: Severe reactions, including angioedema (swelling of the face, lips, or throat), have been reported, and use is contraindicated in patients with known hypersensitivity to the drug.

Population-Specific Considerations

Regulatory documents include specific limitations for certain patient groups:

Hepatic Impairment: Use is generally limited or not recommended in patients with severe liver dysfunction.
Time-Related Patterns: Parkinsonism symptoms have been reported, sometimes severely, within the first two weeks after starting the treatment or increasing the dosage.

This framework of officially listed adverse effects and safety limitations structures the established risk profile of the medication, as defined by government regulatory agencies.

Overdose and Emergency Response

Overdose Manifestations and Required Actions

The official regulatory documents describe specific clinical manifestations and mandated emergency actions in the event of Valbenazine (Ingrezza) overdose.

Overdose may present as an exaggeration of known neurological effects. Officially documented signs include marked somnolence (sedation) and the appearance or worsening of Parkinsonism (Parkinson-like symptoms). These effects are associated with severe outcomes, including cases of severe Parkinsonism that may necessitate professional intervention.

Life-Threatening Risks

The regulatory labeling highlights the potential for QT interval prolongation, a significant cardiovascular risk that may lead to life-threatening Arrhythmias. This risk is a central component of the overdose profile.

Emergency Response

Official guidance requires seeking immediate medical attention if a severe manifestation, such as signs of cardiac abnormality or significant neurological change, is suspected. The mandated emergency response in any case of suspected overdose is to consult a Certified Poison Control Center immediately.

Supportive Management

As no specific antidotes are known for Valbenazine, management focuses on providing supportive care alongside close medical supervision and continuous monitoring. Medical professionals are instructed to consider the possibility of multiple drug involvement and to include assessment of the QT interval due to the recognized cardiac risk.

Therapeutic Uses of Ingrezza

What Ingrezza Treats: Main Uses and Benefits

Ingrezza (Valbenazine) is commonly used as a prescription medicine for adults, focusing on providing targeted symptomatic support for chronic movement disorders. The use of valbenazine may assist with maintaining functional stability in situations where patients experience these disruptive symptoms. Its therapeutic scope is relevant in contexts involving two specific neurological conditions: Tardive Dyskinesia (TD) and chorea associated with Huntington's disease (HD).

Symptom Relief and Functional Support

This medication is relevant for use in adults experiencing symptoms of increased neurological or muscular activity. It helps manage symptom patterns that include repetitive movements of the face, tongue, and limbs (dyskinesia), as well as unpredictable jerking or twitching motions (chorea). The treatment is relevant when symptoms interfere with daily functioning, such as eating or speaking.

“This symptomatic support is intended to help ease the overall symptom burden that affects routine comfort and stability.”

By moderating the intensity of unwanted movements, the treatment assists with maintaining functional stability and supports the patient during difficult episodes by easing distress. This approach supports day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Involuntary Movements The medication is relevant for easing symptoms of unwanted, uncontrolled movements that create noticeable functional strain, particularly when managing the chronic manifestations of TD and HD chorea.

Regulatory References

NIH-published data on Valbenazine

Eligibility and Restrictions for Use

Ingrezza (valbenazine) is officially approved for use only in adults (age 18 years and older) for its licensed indications, according to regulatory labeling. The safety and effectiveness of the medication have not been established in the pediatric population.

Formal Contraindications and Eligibility Restrictions

Category	Regulatory Status (Source: FDA Label)
Absolute Contraindication	Contraindicated in patients with a known history of hypersensitivity to valbenazine or any component of the capsule.
Cardiac Conditions	Use should be avoided in patients with congenital long QT syndrome or arrhythmias associated with a prolonged QT interval.
Severe Renal Impairment	Use is not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min).
Hepatic Impairment	Patients with moderate or severe hepatic impairment are eligible, but the use is restricted to a reduced maximum daily dose.
Pregnancy and Lactation	Lactation is not recommended during treatment and for five days after the final dose. Data on use during pregnancy are insufficient to determine risk.

Eligibility is also contingent upon the avoidance of Monoamine Oxidase Inhibitors (MAOIs) and the need for a dose reduction when co-administered with certain strong enzyme inhibitors (e.g., strong CYP3A4 inhibitors) to manage exposure.

What should I know about interactions with other medicines?

Ingrezza (valbenazine) interacts with certain medications and substances, primarily those that affect the CYP450 enzyme system, which is involved in breaking down the drug in the body.

CYP Enzyme Interactions

Type of Interaction	Drug Examples (CYP450 Enzyme)	Recommendation for Ingrezza	Impact on Ingrezza
Strong Inhibitors (CYP3A4)	Ketoconazole, Clarithromycin, Itraconazole	Reduce dose to 40 mg once daily	Increases Ingrezza levels, raising side effect risk
Strong Inhibitors (CYP2D6)	Paroxetine, Fluoxetine, Quinidine	Consider reducing dose based on tolerability	May increase Ingrezza levels, raising side effect risk
Strong Inducers (CYP3A4)	Rifampin, Carbamazepine, Phenytoin, St. John's wort	Avoid concomitant use	Decreases Ingrezza levels, potentially reducing efficacy

Other Significant Interactions

Monoamine Oxidase Inhibitors (MAOIs): Co-administration with MAOIs (e.g., phenelzine, isocarboxazid) is not recommended. This combination may increase the concentration of certain brain chemicals, potentially increasing the risk of serious side effects or reducing Ingrezza's effectiveness.
Digoxin: Ingrezza may increase the concentration of digoxin, a heart medicine, in the blood. If these are taken together, your doctor may need to monitor your digoxin levels and adjust its dosage.
QT Prolonging Drugs: Combining Ingrezza with other drugs that can prolong the QT interval (a measure on an electrocardiogram) may increase the risk of an abnormal heart rhythm.

Mechanism of Action

Selective VMAT2 Inhibition and Dopamine Depletion

The core mechanism involves the selective inhibition of the Vesicular Monoamine Transporter 2 (VMAT2), a protein pump critical for packaging neurotransmitters like dopamine into synaptic vesicles. Valbenazine and its highly active metabolite, [+]-α-HTBZ, prevent this loading process. By blocking VMAT2, unpackaged dopamine is left exposed in the neuron's cytoplasm where it is quickly degraded by enzymes, leading to a substantial depletion of presynaptic dopamine stores.

Attenuating Signaling in CNS Motor Pathways

This reduction in stored dopamine is the molecular mechanism for modulating dopaminergic signaling. With less dopamine available, the nerve impulse releases a diminished quantity of the neurotransmitter into the synaptic cleft. This attenuation of dopaminergic output influences the activity within the central nervous system's motor control pathways (basal ganglia circuitry). The physiological consequence is an influence on the neurochemical equilibrium, which promotes regulation of motor control circuitry activity.

Dosage and Administration Information

Ingrezza is intended for oral administration as a prescription-only medication. It is available in capsule strengths of 40 mg, 60 mg, and 80 mg, designed for once-daily use. The procedural guidelines for Ingrezza establish a standardized titration regimen over time. Treatment typically initiates with a starting dose of 40 mg once daily. The dose is then adjusted, often reaching the recommended maintenance dose of 80 mg once daily, which is also the maximum permissible daily amount. The schedule for increasing the dose is based on the condition being managed; for example, dose increases for chorea associated with Huntington’s disease occur in 20 mg increments every two weeks.

A key administration condition is flexibility regarding food: Ingrezza can be taken with or without food. The medication can be swallowed whole, or the contents of the capsule can be opened and sprinkled onto a small quantity of soft food, such as yogurt or applesauce. This drug-food mixture must be consumed immediately or within two hours of preparation. Importantly, standard instructions dictate special handling: the capsules must not be crushed or chewed when swallowed whole, and the contents must not be mixed with milk or drinking water.

Furthermore, specific dose adjustments are required for certain populations to maintain appropriate exposure. Patients with moderate or severe hepatic impairment, or individuals known as CYP2D6 poor metabolizers, are recommended to take a maximum daily dose of 40 mg. If a patient misses a dose, they should take the next dose at the regularly scheduled time, rather than taking a double dose. This structure is designed to support consistent application of the treatment.

Recent Clinical Evidence

Research evidence / Overview of studies for Ingrezza

Evidence for use in Tardive Dyskinesia (TD)

Studies help show what has been observed so far, including findings from pivotal Phase 3 randomized, double-blind, placebo-controlled trials (RCTs). These controlled studies examined TD symptoms, which are often characterized by functional limitations, in adult participants. The core research primarily examined changes in symptom intensity using the Abnormal Involuntary Movement Scale (AIMS) total score.

Research explored characteristics of symptoms over defined time intervals, typically lasting six weeks in the initial controlled period. Findings describe patterns observed in these studies regarding the AIMS score, compared to those participants who received a non-active treatment (placebo). This evidence provides context for short-term symptom patterns in the studied populations.

However, follow-up durations for the core controlled trials were limited. Therefore, long-term effects are not fully established under controlled conditions. The lack of a clear, standardized threshold for what constitutes a minimum meaningful change on the AIMS scale also means that certainty remains low regarding the clinical relevance of the measured differences.

Evidence for use in Chorea associated with Huntington's Disease (HD)

This medication was evaluated in the context of involuntary movements (chorea) in adults with Huntington's disease (HD). This research includes a pivotal Phase 3 randomized, double-blind, placebo-controlled trial. The main outcome was tracked using the Unified Huntington’s Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) score.

Studies monitored the chorea severity measurements over a 12-week course. Findings describe patterns observed in the studies related to the TMC score, compared to the placebo group. Research provides insight into short-term changes in this patient group.

Long-Term Studies and Follow-Up Duration

Studies for both TD and HD chorea included open-label extension phases that extended the follow-up durations for participants. For TD, open-label follow-up extended up to 48 weeks, and for HD chorea, observational periods reached approximately three years. This research examined data related to physical discomfort and was applied in observational settings.

These extended studies reported how symptoms evolved in the observed populations. However, the design of these studies means they were not placebo-controlled, which limits the assessment of patterns over time compared to an inactive treatment.

What is Still Uncertain About Ingrezza

Evidence highlights that the short duration of the core placebo-controlled trials for both indications is a recognized limitation. There is limited information for long-term outcomes in a controlled, double-blind research scenario. This gap was noted by regulators, and requirements were issued for post-marketing studies to further explore the persistence of the observed patterns. Research provides context but not individual predictions, and the evidence base continues to evolve.

Frequently Asked Questions (FAQ)

Common questions about Ingrezza (FAQ)

Q: When was Ingrezza first approved by the FDA?

According to the U.S. Food and Drug Administration (FDA), Ingrezza (valbenazine) was first approved on April 11, 2017. This initial approval was for the management of tardive dyskinesia in adults.

Q: How long does it take for Ingrezza to start working?

Official product information suggests that changes in symptoms, as measured in clinical studies, may be observed over several weeks. For tardive dyskinesia, a statistically significant change was generally seen by Week 6. For chorea associated with Huntington’s disease, improvement in clinical studies was observed by Week 12 of treatment.

Q: Does Ingrezza have a generic version available?

The FDA has granted tentative approval for generic versions of valbenazine (the active ingredient in Ingrezza). However, the market availability of a generic version is dependent upon the expiration of patents and regulatory exclusivity periods related to the drug.

Q: What are the effects of Ingrezza on weight or appetite?

Official regulatory documents indicate that 'weight increased' was reported as an adverse reaction in clinical studies, falling under a category of less common events. Changes in appetite are not listed as a common or frequently occurring side effect in the official product information.

How should Ingrezza be stored and disposed of?

Storage and Disposal of Ingrezza (Valbenazine)

Official regulatory information defines specific storage parameters for Ingrezza and Ingrezza Sprinkle to maintain product stability.

Storage Requirements

Formulation	Required Storage Temperature	Environmental Protection
Ingrezza Capsules	59 F to 86 F (15 C to 30 C)	Keep in original container
Ingrezza Sprinkle	68 F to 77 F (20 C to 25 C)	Keep tightly closed to protect from moisture

All forms of this medication must be stored securely, out of the sight and reach of children, with safety caps locked. Storage environments such as bathrooms, which are prone to excess heat and moisture, should be avoided.

Disposal and Stability

When Ingrezza Sprinkle is mixed with soft food, the mixture has a stability limit and must be discarded after a maximum of 2 hours. Unused or expired medication should be disposed of by mixing with an unappealing substance in a sealed bag for household trash or utilizing a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.